Clinical trials: Colorectal Cancer Metastatic to Liver
Colon Cancer Liver Metastasis
Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer
The purpose of this study is to test an experimental anti-cancer immunotherapy called NKR-2 (modified T cells), to treat colorectal cancer with unresectable liver metastases.
- Trial name
- LINK (NCT03370198)
- Testing
- NKR-2 cells
- Where
- Belgium
- Volunteers
- 1 people
- Sponsor
- Celyad Oncology SA
Liver Metastasis Colon Cancer, ctDNA Genotype
Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment
Hepatic arterial infuison chemothearpy (HAIC), targeted therapy, and programmed death-1 (PD-1) inhibitors have been demonstrated to be effective for colorectal cancer liver metastasis (CRCLM).
- Conditions
- Liver Metastasis Colon Cancer, ctDNA Genotype, MSS, Failed From Standard Treatment
- Trial name
- NCT06199232
- Testing
- HAIC+targeted therapy+PD-1 inhibitor
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Peking University
Colorectal Cancer, Metastatic Cancer
Surgery With or Without Radiofrequency Ablation Followed by Irinotecan in Treating Patients With Colorectal Cancer That is Metastatic to the Liver
RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. Combining radiofrequency ablation with surgery may kill more tumor cells.
- Trial name
- NCT00030563
- Testing
- irinotecan hydrochloride, adjuvant therapy, conventional surgery
- Where
- 3 sites in United States, Canada
- Sponsor
- University of Washington
Colon Adenocarcinoma, Liver Metastasis Colon Cancer
LDLT in Non Resectable Colo-rectal Cancer Liver Metastasis
This study is an interventional open label prospective study that aims to assess both overall and disease-free survival of patients treated with LDLT, partial or whole graft LT from deceased donors for unresectable CRLM.
- Trial name
- LIVERMORE (NCT05186116)
- Testing
- Living donor liver transplant, Split liver transplant, RAPID, DDLT
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Modena
Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
- Conditions
- Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer, Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Esophageal Cancer
- Trial name
- NCT03538028
- Testing
- INCAGN02385
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Incyte Biosciences International Sàrl
Colorectal Cancer Liver Metastases
Phase II Study of Regorafenib and Toripalimab Combined With RFA in Patients With CRCLM
The incidence of colorectal cancer liver metastasis is high and the prognosis is poor. Improving the treatment effect of colorectal cancer liver metastasis is the key to improving the prognosis of colorectal cancer patients.
- Trial name
- NCT05485909
- Testing
- Radiofrequency ablation, Regorafenib and Toripalimab Combination
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Sun Yat-sen University
Advanced RAS-Mutated Colorectal Cancer With Liver Metastases (CRLM)
A Single-Arm, Phase II Study of Retlirafusp Alfa in Combination With XELOX and Bevacizumab for the First-Line Treatment of Advanced RAS-Mutated Colorectal Cancer With Liver Metastases (CRLM)
This single-arm phase II trial enrolls patients with RAS-mutant, microsatellite-stable (MSS) unresectable colorectal cancer liver metastases receiving first-line treatment with Retlirafusp alfa combined with XELOX (capecitabine…
- Trial name
- NCT07797244
- Testing
- Retlirafusp alfa+XELOX+Bevacizumab Treatment
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Dai, Guanghai
Colorectal Cancer, Metastatic Cancer
Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as melphalan, leucovorin, oxaliplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00103298
- Testing
- FOLFOX regimen, fluorouracil, isolated perfusion
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Colon Cancer Liver Metastasis, Colon Cancer
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
The purpose of this study is to study the way radioembolization works by collecting biopsy samples of participants' tumors after the procedure.
- Conditions
- Colon Cancer Liver Metastasis, Colon Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
- Trial name
- NCT04668872
- Testing
- Y90 TARE, PET/CT, PET/MRI
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Cancer, Metastatic Cancer
Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer
The purpose of this study is to find the highest dose that can be given safely to people who have had liver disease resected. This is a Phase I study.
- Trial name
- NCT00059930
- Testing
- FOLFOX regimen, dexamethasone, floxuridine
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Stage III Breast Cancer, Stage IV Breast Cancer
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using…
- Conditions
- Stage III Breast Cancer, Stage IV Breast Cancer, Stage III Lung Cancer, Stage IV Lung Cancer
- Trial name
- NCT04985357
- Sponsor
- Travera Inc
Metastatic Colorectal Cancer
FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-type
BACKGROUND: For patients with liver-limited metastatic colorectal cancer (mCRC), complete resection of liver metastases is the only potentially curative treatment.
- Trial name
- FORBES (NCT02350530)
- Testing
- FOLFOXIRI + Bevacizumab, FOLFOXIRI
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer
VXM01 Phase I Study in Patients With Metastatic Colorectal Cancer With Liver Metastasis
Phase I study in patients with metastatic colorectal cancer with liver metastasis under second or third line therapy to examine safety, efficacy, and immune biomarkers after treatment with VXM01
- Trial name
- NCT02718430
- Testing
- VXM01
- Where
- Germany
- Volunteers
- 6 people
- Sponsor
- Vaximm GmbH
Colorectal Cancer Stage IV
Impact de la Marge de résection Sur la Survie à Long Terme et le Taux de récidive Des Patients Atteints de Cancers Colorectaux opérés au CHUS Entre 2006 et 2016 Pour Des métastases hépatiques
We retrospectively looks at the impact of the margin status and its size in mm on the recurrence rate in colo-rectal liver metastasis surgery.
- Trial name
- NCT05164419
- Volunteers
- 170 people
- Sponsor
- Université de Sherbrooke
Colorectal Carcinoma Metastatic in the Liver, Metastatic Colorectal Carcinoma
An Imaging Agent (I-124 M5A) in Detecting CEA-Positive Liver Metastases in Patients With Colorectal Cancer
This phase I trial studies how well an imaging agent called I-124 M5A works in detecting CEA-positive colorectal cancer that has spread to the liver.
- Conditions
- Colorectal Carcinoma Metastatic in the Liver, Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8
- Trial name
- NCT03993327
- Testing
- Iodine I 124 Monoclonal Antibody M5A, Positron Emission Tomography
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- City of Hope Medical Center
Liver Metastasis, Colorectal Carcinoma
A Prospective Colorectal Liver Metastasis Database With an Integrated Quality Assurance Program
This prospective database has two main objectives; to evaluate the complication rates, 30-day and 90-day mortality from different surgical strategies for unresectable, borderline resectable or initially unresectable liver…
- Trial name
- CLIMB (NCT02218801)
- Testing
- Evaluation of treatment for liver metastasis
- Where
- 16 sites in Austria, Belgium and 10 more
- Volunteers
- 219 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Metastatic Carcinoma in the Liver, Recurrent Colorectal Carcinoma
Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver
This early phase IIA trial studies how well celecoxib, recombinant interferon alfa-2b, and rintatolimod work in treating patients with colorectal cancer that as spread to the liver.
- Conditions
- Metastatic Carcinoma in the Liver, Recurrent Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7
- Trial name
- NCT03403634
- Testing
- Celecoxib, Laboratory Biomarker Analysis, Recombinant Interferon Alfa-2b
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Roswell Park Cancer Institute
Liver Metastasis Colon Cancer
Improving Survival of COlorectal LIver Metastases by RFA-mediated Immunostimulation
To examine radio frequency ablation as a treatment supplement to stimulate immunogenicity and improve survival for patients undergoing curative-intent surgery for colorectal liver metastases.
- Trial name
- ISCOLIM (NCT04798898)
- Testing
- RFA (radiofrequency ablation)
- Where
- Denmark
- Volunteers
- 200 people
- Sponsor
- University of Aarhus
Colorectal Cancer, Metastatic Cancer
Gene Therapy in Treating Patients With Colon Cancer That Has Spread to the Liver
RATIONALE: Gene therapy may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the safety of NV1020 in patients who have colon cancer that has spread to the liver and has not responded to…
- Trial name
- NCT00012155
- Testing
- NV1020
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, Head and Neck Cancers
Surgical Margin Assessment Using Intra-operative High-resolution PET/CT in Patients With Cancers Referred to Surgical Resection, an Exploratory Pilot Study
Reoperation is often required in surgical oncology because of positive resection margins and is associated with substantial physical, psychological, and economic consequences.
- Conditions
- Breast Cancer, Head and Neck Cancers, Lung Cancer, Sarcoma
- Trial name
- SMART-PET (NCT07884487)
- Testing
- FDG radiotracer
- Where
- Belgium
- Volunteers
- 250 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain